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Abstract
Background: The aim of the study was to evaluate the role of cardiopulmonary exercise test-
ing (CPET) parameters in assessing exercise capacity improvement after percutaneous pulmo-
nary valve implantation (PPVI). Additionally, it aimed to determine if there are any baseline 
characteristics influencing that change.
Methods and results: The study comprised 32 patients (mean age 26 ± 9); 53% males;  
diagnosis: tetralogy of Fallot (n = 18), pulmonary atresia (n = 6), Ross procedure (n = 4), 
other (transposition of great arteries, pulmonary stenosis, double outlet right ventricle, common 
arterial trunk type II — n = 4) who underwent successful PPVI due to right ventricular out-
flow tract dysfunction (predominant pulmonary regurgitation — n = 17, predominant pulmo-
nary stenosis — n = 15). Treadmill CPET was performed before and a year after PPVI along 
with clinical evaluation, cardiac magnetic resonance and transthoracic echocardiography. 
Twelve months post successful PPVI (pulmonary valve competence restoration and pulmonary 
gradient reduction from 58.8 ± 47.1 to 26.6 ± 10.8 mm Hg) there was a significant decrease 
in the ventilatory equivalent for CO2 at peak exercise (EQCO2) (25.3 ± 3.3 to 24.3 ± 3.0,  
p = 0.04) and oxygen consumption at peak exercise (pVO2) (20.4 ± 5.0 to 22.6 ± 5.3 mL/ 
/kg/min, p = 0.04). Improved EQCO2 correlated with an increase in right and left ventricular 
ejection fraction (respectively R = –0.57, p = 0.002; R = –0.56, p = 0.002). In this study, no 
baseline factors that might affect improvement in exercise function were found.
Conclusions: Successful PPVI leads to an improvement in exercise capacity and hemody-
namic response to exercise. The correlation between the improvement in EQCO2 or peak VO2 
and baseline characteristics was too weak to reliably identify the group of patients that will 
benefit from the procedure. (Cardiol J 2015; 22, 3: 343–350)
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Introduction
Patients with certain types of congenital heart 
defect need to undergo surgical repair of right ven-
tricular (RV) outflow tract (RVOT) in their early 
infancy. After some years, the implanted RVOT 
conduits almost inevitably degenerate causing 
RV obstruction and/or regurgitation, which leads 
to progressive dysfunction of the RV requiring 
further surgical interventions. Consequently, 
those patients need to be subjected to multiple 
surgeries, each connected with an increasing 
risk. Percutaneous pulmonary valve implantation 
(PPVI) is a promising alternative for this group 
of patients. Some improvement of hemodynamic 
parameters after the procedure has been reported 
in several trials [1–4]. However, it is difficult to 
determine optimal timing for the intervention. 
Impaired physical capacity is reported to be the 
one of the first signs of decline in the RV function 
in asymptomatic patients [5, 6]. The aim of this 
study was to investigate whether PPVI leads to 
an improvement in exercise function and which 
patients might benefit from the procedure when 




It is a retrospective cohort study. Out of 37 con-
secutive patients who underwent successful PPVI 
in the Institute of Cardiology in Warsaw, Poland, in 
years 2008–2012, 32 patients were investigated. 
The qualification of patients included: clinical ex-
amination, transthoracic echocardiography (TTE), 
cardiovascular magnetic resonance (CMR) and 
CPET performed before and 1 year after PPVI. Five 
patients were excluded due to inappropriate CPET 
performance (different protocol for a particular sub-
ject has been used before and after PPVI).
The study group consisted of 17 men and 
15 women who underwent surgical repair of con-
genital heart defect in the past and were qualified 
for PPVI due to pulmonary valve dysfunction. The 
group was divided into two subgroups basing on the 
type of dominant lesion. Group 1 consisted of pa-
tients with predominant pulmonary stenosis (PS), 
significant pulmonary gradient, the pulmonary 
regurgitation fraction (PRF) < 25%, and maximally 
mild PR in echocardiography. Group 2 consisted of 
patients with predominant pulmonary regurgitation 
(PR), PRF ≥ 25% or significant PR in echocardi-
ography. Inclusion criteria for PPVI were based 
on surgical indications for RVOT reoperation [7]. 
Percutaneous pulmonary valve implantation using 
either Melody® valve (n = 20) or SAPIEN™ THV 
(n = 12) was performed according to the protocol 
described previously [1, 8].
Study protocol 
The study was approved by the local Research 
Ethics Committee. CPET, CMR and TTE were 
performed 1 day – 5 months before PPVI and 1 year 
after the procedure along with the assessment of 
the New York Heart Association (NYHA) functional 
class. Each subject gave a signed informed consent.
Cardiopulmonary exercise testing
Cardiopulmonary exercise treadmill test was 
performed approximately 2 h after medications 
and a light breakfast in all patients. Each subject 
performed a symptom limited CPET according to 
a Ramp protocol or modified Bruce protocol (al-
ways the same protocol for a particular subject 
before and after PPVI so that each patient would be 
a control for him/herself). The test was performed 
using a Schiller treadmill (Carrollton, USA) which 
was connected to a computerized breath-by-breath 
spiroergometry system (ZAN 600, ZAN Mess-
geräte GmbH, Germany).
Oxygen consumption (VO2) was measured 
continuously using breath-by-breath analysis and 
used as an index of exercise capacity. Peak VO2 
was defined as the highest oxygen uptake level 
achieved during the final 30 s of CPET. The formula 
used for the prediction of VO2 (in mL/kg/min) was 
the Wasserman standard calculation, which incor-
porates sex, age, height, and weight of the subject 
and is valid for patients aged over 20 years [9]. 
Twelve-lead electrocardiogram (ECG) and heart 
rate (HR) were recorded continuously at rest, 
during CPET and during recovery until HR, ECG, 
and VO2 returned to the baseline values. Blood 
pressure (BP) was measured manually every 2 min 
using a sphygmomanometer.
Subjects were encouraged to exercise until 
they reached a self-determined limit of their func-
tional capacity (perceived exertion or dyspnea) or 
until a physician terminated the test according to 
the European Society of Cardiology guidelines [10].
All CPET procedures were supervised by 
a nurse and a cardiologist. The parameters measured 
were the duration of workload, peak VO2 [mL/kg/ 
/min], % predicted peak VO2, minute ventilation (VE 
[L/min]), respiratory exchange ratio, HR [bpm], BP 
[mm Hg], breathing frequency [L/min], and ventila-
tory equivalents for CO2 (EQCO2).
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Cardiovascular magnetic resonance
The data derived from CMR were collected 
using a 1.5 T scanner (Avanto, Siemens, Erlangen, 
Germany). The acquisition included steady-state 
free precision images in left ventricle (LV) long axis 
(2-, 3- and 4-chamber views) as well as a stack of 
short axis cross sectional views covering the ven-
tricles from base to apex and phase contrast flow 
according to the instructions described previously 
[11]. After manual determination of end-diastolic 
and end-systolic endocardial outline, dedicated 
software (MASS 6.2.1, Medis, Leiden, the Nether-
lands) was used to assess RV and LV volumes and 
sizes. All volumes were indexed by body surface 
area (BSA) and expressed in mL/m2. The degree 
of PRF was calculated with the dedicated software 
(Argus, Siemens, Erlangen, Germany).
Transthoracic echocardiography
Transthoracic echocardiography was per-
formed using an echocardiographic system (Vivid 7, 
GE Medical Systems, Milwaukee, USA). The de-
gree of RVOT gradient was derived from the peak 
velocity obtained by continuous-wave Doppler 
using the modified Bernoulli equation. Pulmonary 
regurgitation was evaluated on the basis of vena 
contracta. The regurgitant jet exceeding 6 m in 
width was found to be significant. The remainder 
was considered to be small or moderate.
Statistical analysis
All continuous variables are expressed as 
mean ± standard deviation. Paired Student’s 
t-test was used to compare changes in CPET, CMR, 
TTE parameters for normally distributed variables 
before and after PPVI. Non-normally distributed 
variables were compared with the aid of the Signed 
Rank test. The normality of distribution was as-
sessed using the Shapiro-Wilk test. Correlations 
between changes in CPET parameters and (a) ba-
seline CMR and TTE parameters, (b) changes in 
CMR and TTE were tested using Pearson’s test. 
The level of significance was defined at p < 0.05. 
All statistical analyses were performed with the 
use of MedCalc 10.0.2.0 statistical software (Med-
Calc, Mariakerke, Belgium).
Results
The patients’ characteristics are shown in 
Table 1. Thirty-two patients met the inclusion 
criteria for the study. The mean age at the study 
onset was 26 ± 9 years; 17 patients were diag-
nosed with predominant regurgitation, 15 with 
predominant stenosis. The most common primary 
diagnosis was tetralogy of Fallot (56%) followed 
by pulmonary atresia (n = 6), aortic valve disease 
(Ross procedure) (n = 4), transposition of great 
arteries (n = 1), pulmonary stenosis (n = 1), 
double outlet RV (n = 1), common arterial trunk 
Table 1. Demographic data.
Parameter Total population (n = 32)
Age [years] 26 ± 9










Baseline diagnosis: Tetralogy of Fallot
Pulmonary atresia
Aortic valve stenosis, Ross procedure
TGA, Rastelli procedure
Pulmonary stenosis
Double outlet right ventricle
















NYHA — New York Heart Association functional classification; TGA — transposition of great arteries
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Figure 2. Results of peak oxygen uptake (pVO2) and ventilatory equivalent for oxygen consumption (EQCO2) before 
and 12 months after percutaneous pulmonary valve replacement (PPVI); PS — predominant stenosis; PR — predomi-
nant regurgitation.
type I (n = 1). The patients had an average of two 
surgeries prior to PPVI. The mean time since the 
last intervention was 14.7 years. PPVI led to valve 
competence restoration observed in all patients 
1 day after the procedure.
In the subgroup of patients with significant PS, 
pulmonary gradient decreased from 94.5 (range 
41–200) to 38.9 (range 22–68). These results re-
mained stable in a 1-year observation.
Additionally, we detected a statistically signifi-
cant decrease in RV end-diastolic volume (RVEDV) 
and end-systolic volume (RVESV) and an increase 
in RV ejection fraction (EF) (p = 0.003; p = 0.0003; 
p = 0.008, respectively). When comparing the 
group of patients with PS with patients with PR, it 
appeared that the statistically significant decrease 
in RVEDV was noted in the latter group only. The 
end-diastolic volume of LV and LVEF increased 
(respectively p < 0.0001; p = 0.04).
Twelve months after PPVI no worsening in 
NYHA functional class was observed in any patient.
Furthermore, every symptomatic patient (with 
NYHA functional class II or above) who underwent 
the procedure improved in his/her functional class. 
The remaining 8 asymptomatic patients claimed 
significant improvement in physical capacity (Fig. 1).
PPVI led to a statistically significant increase 
in peak VO2 (20.4 ± 5.0 vs. 22.6 ± 5.3 mL/kg/ 
/min; p = 0.04) (Fig. 2A). There was also a reduc-
tion in EQCO2 at peak oxygen uptake (25.3 ± 3.3 
vs. 24.3 ± 3.0; p = 0.04). After comparing PR and 
PS groups, a statistically significant reduction in 
EQCO2 was observed only in PS group (25.1 ± 
± 2.5 vs. 23.4 ± 2.4; p = 0.03) (Fig. 2B). Systolic 
BP at maximal effort increased after the proce-
dure (135.8 ± 26.3 vs. 154.1 ± 29.5 mm Hg; p < 
< 0.0001). The duration of workload was elongated 
after the intervention (621 ± 204 vs. 676 ± 182 min; 
p = 0.0004).
There was no correlation between improve-
ment in peak VO2 and either of the examined 
baseline CMR or TTE characteristics (Table 2).
An improvement in EQCO2 (lower values of 
∆EQCO2) correlated with baseline: greater mass 
of RV or LV, higher RVOT maximal gradient and 
PRF (R = –0.38; p = 0.047; R = –0.35; p = 0.06; 
R = –0.46; p = 0.01; R = –0.35; p = 0.08, respec-
tively) (Table 2). The primary outcome defined as 
an improvement in EQCO2 (decrease in EQCO2 
Figure 1. New York Heart Association (NYHA) functional 
class before and after percutaneous pulmonary valve 
replacement (PPVI); n — number of patients.
346 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 3
Table 2. Relationship between change in peak oxygen consumption (VO2) and ventilatory equivalents 
for CO2 (EQCO2) and baseline magnetic resonance imaging and echocardiography parameters.
∆pVO2 ∆EQCO2
N R P N R P
Right ventricular end-diastolic volume index [mL/m2] 28 0.25 NS 28 0.07 NS
Right ventricular end-systolic volume index [mL/m2] 28 0.17 NS 28 0.04 NS
Right ventricular ejection fraction [%] 28 –0.07 NS 28 0.19 NS
Right ventricular mass [ml/m2] 28 0.13 NS 28 –0.38 0.047
Left ventricular end-diastolic volume index [mL/m2] 28 –0.23 NS 28 –0.17 NS
Left ventricular end-systolic volume index [mL/m2] 28 –0.08 NS 28 –0.18 NS
Left ventricular ejection fraction [%] 28 –0.13 NS 28 0.14 NS
Left ventricular mass [mL/m2] 28 –0.24 NS 28 –0.35 0.06
Right ventricular outflow tract maximal gradient 28 –0.04 NS 28 –0.46 0.01
Pulmonary regurgitation fraction [%] 26 –0.03 NS 26 –0.35 0.08
N — number of patients; R — Pearson correlation coefficient; ∆ — indicates change (from baseline to 1 year post implantation); NS — statistically 
non-significant change or no trend; Bold indicates statistically significant change or trend
Table 3. Univariate regression analysis of potential predictors of changes inpeak oxygen consumption 
(VO2) uptake and ventilatory equivalents for CO2 (EQCO2).
∆pVO2 ∆EQCO2
N R P N R P
∆ Right ventricular end-diastolic volume index [mL/m2] 28 –0.35 0.07 28 0.12 NS
∆ Right ventricular end-systolic volume index [mL/m2] 28 –0.25 NS 28 0.20 NS
∆ Right ventricular ejection fraction [%] 28 0.02 NS 28 –0.57 0.002
∆ Right ventricular mass [mL/m2] 26 –0.15 NS 26 0.27 NS
∆ Left ventricular end-diastolic volume index [mL/m2] 28 0.09 NS 28 –0.01 NS
∆ Left ventricular end-systolic volume index [mL/m2] 28 0.06 NS 28 0.43 0.02
∆ Left ventricular ejection fraction [%] 28 –0.01 NS 28 –0.56 0.002
∆ Left ventricular mass [mL/m2] 27 0.40 0.04 27 0.36 NS
∆ Right ventricular outflow tract maximal gradient 27 0.10 NS 27 0.44 0.02
N — number of patients; R — Pearson correlation coefficient; ∆ — indicates change (from baseline to 1 year post implantation); NS — statistically 
non-significant change or no trend; Bold indicates statistically significant change or trend
after the procedure) correlated significantly with 
an increase in EF of the RV and LV (Table 3).
Discussion
Optimal timing for the intervention in patients 
with RVOT dysfunction has been widely debated. 
The group of patients subjected to PPVI is varied 
in terms of primary diagnosis, symptoms, number 
of interventions, type of dominant lesion, and 
anatomy of the heart. Investigators try to define 
the baseline characteristics related to an improve-
ment after PPVI, most typically acknowledged by 
the assessment of ventricular end-systole and end-
-diastole volumes, or CPET [11–14]. The reported 
factors that are believed to influence short- and/or 
long-term results include: type of dominant lesion 
[4, 15]; baseline RVEDV [16, 17]; and baseline 
peak VO2 value [18]. In this study, no baseline fac-
tors that might affect an improvement in exercise 
function were found. This, however, might be due 
to small, heterogeneous patient group, therefore 
further research is needed.
Previous studies remain unequivocal about the 
influence of PPVI on exercise performance. Con-
trary to surgical replacement of pulmonary valve 
(PVR), PPVI does not involve any incisions in the 
myocardium — a frequent cause of a conduction 
block and arrhythmias, which worsen heart func-
tion [19]. PPVI leading to restoration of pulmonary 
valve function, similarly to PVR, simultaneously 
being a less invasive method, could be expected to 
have a positive effect on heart function and conse-
quently exercise performance. There is, however, 
www.cardiologyjournal.org 347
Elżbieta Katarzyna Biernacka et al., Influence of PPVI on exercise capacity
Figure 3. Results of peak oxygen uptake (pVO2) and ventilatory equivalent for oxygen consumption (EQCO2) before 
and 12 months after percutaneous pulmonary valve replacement (PPVI); D — indicates change (from baseline to 1 year 
post implantation); R — Pearson correlation coefficient; RVEDV — right ventricular end-diastolic volume; RVEF — 
right ventricular ejection fraction; RVOT — right ventricular outflow tract.
no clear evidence of improvement in cardiopulmo-
nary function after the procedure [11, 15, 18, 20, 21]. 
In our study, a small but significant improvement 
in peak VO2 and EQCO2 were reported.
In order to understand the outcomes of the 
conducted experiments, patients’ magnetic reso-
nance imaging and TTE were investigated and then 
the findings were correlated with CPET data. An 
important finding derived from the study was that 
the improvement in RV function following RVOT 
gradient reduction due to PPVI, led to exercise 
function improvement (Fig. 3). Healthy subjects 
respond to exercise by increasing RV pressure and 
pulmonary blood flow [22]. In patients with RVOT 
dysfunction there is poor exercise performance 
resulting from (1) submaximal pulmonary circula-
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tion, (2) pressure overload of RV. In line with this 
description and previous studies, we reported 
that in patients with congenital heart disease with 
pulmonary conduit dysfunction exercise capacity 
is significantly impaired [18, 23].
In terms of RV overload, patients with PR dif-
fer from patients with PS. PR leads to RV volume 
overload, observed as an increase in RVEDV that 
could be followed in our study. In patients with PS, 
however, abnormal loading conditions lead to an 
increase in RVESV with no change in RVEDV. In 
this group, PPVI leads to reduction in RVESV, with 
no change in RVEDV. The results are consistent 
with the findings by Coats et al. [11, 20].
Releasing RV from volume and pressure over-
load due to PPVI combined with increased RVEF 
might be assigned to a better pulmonary arterioles 
blood flow. Consequently, increased pre-load im-
proves LVEF. The relocation of blood towards pulmo-
nary circulation enhances the blood saturation, which 
combined with an increase in biventricular effective 
stroke volume, results in improved physical capacity 
(examined by change in peak VO2 and ventilatory 
equivalent for CO2). Also, the subjective component, 
reflected by the duration of workload in CPET and 
NYHA classification, clearly indicated an improve-
ment in cardiopulmonary function. These findings 
are consistent with previous studies examining the 
correlation between changes in RV and LV functions 
and exercise capacity. Lurz et al. [4] described post-
procedural improvement in peak oxygen uptake and 
minute ventilation/carbon dioxide elimination slope 
as a result of RV and LV effective stroke volume 
increase during exercise in patients with PS, which 
is consistent with our findings.
Our data suggest a clear positive influence of 
PPVI on peak VO2 and a link between peak VO2 
and magnetic resonance imaging parameters con-
nected with the right heart physiology. In our study, 
however, we observed a significant but small im-
provement in peak VO2. The cause of that might be 
a considerably small group of patients included in 
the study and different factors affecting peak VO2, 
such as: oxygen carrying capacity of the blood, pe-
ripheral blood flow, extraction by the tissue, pulmo-
nary diseases, quantity of exercising muscles, fat- 
-free mass. Another limitation of using peak VO2 in 
assessing exercise performance is the inaccuracy 
of measuring external work rate when performing 
a treadmill test. Peak VO2 is acknowledged as 
a gold standard for cardiorespiratory fitness. In clini-
cal testing, however, we should make allowances 
for symptom limitation of exercise, which is often 
the case in patients with congenital heart disease.
An improvement in medical databases is typi-
cally defined with regard to standards. In the case 
of patients with congenital heart disease, however, 
the physiology of the heart differs from that in other 
individuals, moreover it changes during exercise. 
That is why acknowledging the indicators of “im-
provement” is not simple. In the case of patients 
with pulmonary regurgitation, we observed post-
procedural reduction in RVEDV as a result of reduced 
blood retrograde flow through the pulmonary valve 
during diastole. That supports the findings by Coats 
et al. [11], who explained that RV in this group of 
patients is on decompensatory limb of the Starling 
curve at baseline which shifts leftwards back to the 
compensatory limb following PPVI. The group of 
patients with predominant stenosis show a different 
pattern of RV hemodynamics following the proce-
dure. The decompensated state, contrary to what is 
seen in PR group, is a result of increased afterload. 
Intervention relieves abnormal loading conditions and 
consequently decreases RVESV. These findings are 
similar to the results reported by Coats et al. [20].
In order to describe “improvement” in all 
patients, independently of the type of dominant 
lesion, we chose to use CPET parameters, con-
sidering the fact that impaired physical capacity is 
reported to be the one of the first signs of decline 
in RV function in asymptomatic patients [5]. The 
improvement was assessed using: (1) peak VO2 
— an important parameter defining the limits of 
the cardiopulmonary system [24]; (2) ventilatory 
response to exercise, defined as EQCO2 (VE/VCO2) 
at maximally obtained duration of exercise in both 
tests before and after PPVI. Both elements of 
the EQCO2 formula change with the duration of 
the exercise, which encouraged us to include the 
results at the same time point.
Limitations of the study
The main limitation of the study was a small 
group of patients. It is possible that increasing 
the study population might help find the factors 
associated with the post-procedural improvement. 
Additionally, the follow-up period was rather short 
so we were unable to comment on a long-outcome 
of the procedure (over 1 year). The mean respira-
tory exchange ratio was 0.98, which indicated that 
in some patients, the physical effort was sub-
maximal, consequently their results might have 
been underestimated.
The Wasserman standard formula, used for 
calculating predicted peak VO2 is valid for patients 
aged over 20 years. Five out of 29 patients included 
in the study were under the age of 20 years, which 
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made us use peak VO2 instead of predicted peak 
VO2 for further calculations.
Conclusions
The results directed us to three major con-
clusions: (1) PPVI resulted in an improvement in 
the duration of workload, peak oxygen uptake and 
EQCO2. (2) Ventilatory equivalent for CO2 and 
peak VO2 were convenient for the assessment of 
post-procedural improvement. (3) The correlation 
between an improvement in EQCO2 or peak VO2 
and baseline characteristics was too weak to reli-
ably identify the group of patients that will benefit 
from the procedure.
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